Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ezatiostat
- Development stage
- Phase 2
- Lead developer
- Telik
- Modality
- Peptides, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Ezatiostat is a small molecule peptidomimetic inhibitor of glutathione S-transferase P1-1 (GSTP1-1), designed to stimulate hematopoiesis by promoting the formation and differentiation of bone marrow progenitor cells into granulocytes, monocytes, erythrocytes, and platelets. It acts intracellularly on the MAPK signaling pathway by activating ERK2 and disrupting GSTP1–1 interactions with JNK1. Ezatiostat has demonstrated myelostimulant activity in preclinical models and human bone marrow cultures. It is being investigated primarily for the treatment of myelodysplastic syndrome (MDS), a condition characterized by insufficient production of blood cells due to dysfunctional bone marrow. The drug may also have potential as an adjunct therapy to counteract cytopenias caused by chemotherapy[1][2][4][5].
- Brand names
- Telintra
- Other names
- gamma-Glutamyl-S-(benzyl)-cysteinyl-R(-)-phenylglycine diethyl esterezatiostat hydrochloride
02
Targets
GSTP1 (Glutathione S-transferase P)
Beyond the preview
Go deeper on ezatiostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ezatiostat.